{"id":"pq-0-4","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Gastrointestinal disturbances"},{"rate":"5-15%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"PQ (0.4) specifically targets the heme detoxification pathway in Plasmodium parasites, converting heme into hemozoin, which is toxic to the parasite. This action leads to the destruction of the parasite within the host's red blood cells.","oneSentence":"PQ (0.4) is an antimalarial drug that works by disrupting the parasite's ability to metabolize heme, leading to its death.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:29:51.722Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Radical cure of Plasmodium vivax malaria"},{"name":"Treatment of Plasmodium ovale malaria"}]},"trialDetails":[{"nctId":"NCT01838902","phase":"PHASE3","title":"Primaquine's Gametocytocidal Efficacy in Malaria Asymptomatic Carriers","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2013-08","conditions":"Malaria","enrollment":467},{"nctId":"NCT02654730","phase":"PHASE2, PHASE3","title":"Evaluation of the Safety of Primaquine in Combination With Dihydroartemisinin-piperaquine in G6PD Deficient Males in The Gambia","status":"TERMINATED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2015-12","conditions":"Malaria","enrollment":61},{"nctId":"NCT02174900","phase":"PHASE2, PHASE3","title":"Safety of Primaquine + Artemether-lumefantrine in G6PD Deficient Males With an Asymptomatic Malaria Infection (SAFEPRIM)","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2014-10","conditions":"Malaria","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":137,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Primaquine"],"phase":"phase_3","status":"active","brandName":"PQ (0.4)","genericName":"PQ (0.4)","companyName":"London School of Hygiene and Tropical Medicine","companyId":"london-school-of-hygiene-and-tropical-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PQ (0.4) is an antimalarial drug that works by disrupting the parasite's ability to metabolize heme, leading to its death. Used for Radical cure of Plasmodium vivax malaria, Treatment of Plasmodium ovale malaria.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}